| DB ID | MyCo_7103 |
| Title | The Clinical Significance of Serum 1,3-β-D-Glucan For the Diagnosis of Candidemia in Severe Burn Patients |
| Year | 2019 |
| PMID | 30365029 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | Severe Burn Patients |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | This study was conducted according to the guidelines and with the approval of the ethics committee of Kyorin University. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | During the study period, 255 burn patients were admitted to Kyorin University Hospital Burn center. After selection, 51 severe burn patients were included. |
| Cohort No. | 51 |
| Age Group | 11–95 |
| P Value | None |
| Sensitivity | 1 |
| Specificity | 0.95 |
| Positive Predictive Value | 83 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Analytic |
| Analysis Method | Wako BDG Test |
| ELISA kits | Wako BDG test Kit (Wako Pure Chemical Industries, Osaka, Japan). |
| Assay Data | None |
| Validation Techniques used | Wako BDG Test |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
